Imperative Care has announced findings from a post-hoc analysis of the SYMPHONY-PE trial evaluating the effect of early mechanical thrombectomy in patients with intermediate-risk pulmonary embolism (PE). The analysis was published in Circulation: Cardiovascular Interventions.
Imperative Care also announced that more than 500 pulmonary embolism (PE) patients in the US have been treated with the Symphony thrombectomy system to date.
“We set out to establish a new standard in PE treatment by developing a large-bore system that removes the guesswork from thrombectomy and is designed to enable more efficient procedures and real-time decision-making so physicians can focus on what matters most: the patient,” said Fred Khosravi, Imperative Care’s chairman and chief executive officer. “Now, with more than 500 PE patients treated since commercial launch, we are encouraged by the growing physician confidence in Symphony and the continued clinical evidence supporting its procedural efficiency and favourable safety profile.”
“Behind this milestone are hundreds of patients and families affected by PE, and we are grateful to the patients and physicians who have placed their trust in Symphony as they work to deliver timely, life-saving care,” Khosravi added.
The analysis of data from the SYMPHONY-PE trial suggests that treating patients within 12 hours of diagnosis may be associated with greater improvement in acute haemodynamic and right ventricle measures compared to treatment after 12 hours, with similar safety outcomes between groups.
“While thrombectomy can be beneficial for patients with intermediate-risk PE regardless of when it is performed after diagnosis, data from the SYMPHONY-PE trial add to the growing body of observational evidence suggesting that earlier catheter-based intervention may accelerate cardiac recovery, as reflected by greater reductions in right ventricle-to-left ventricle (RV/LV) ratio and mean pulmonary artery pressure (PAP),” said Sripal Bangalore, lead author of the paper and professor in the Department of Medicine at NYU Grossman School of Medicine in New York, USA.
“Randomised controlled trials are desirable to determine optimal treatment timing and to identify whether patients with certain risk factors are more likely to benefit from early intervention than others.”
The SYMPHONY-PE trial was Imperative Care’s investigational device exemption (IDE) study conducted at 17 US sites that formed the basis for Symphony’s US Food and Drug Administration (FDA) clearance to treat PE in August 2025. Results of the IDE trial were published in the November 2025 issue of Circulation: Cardiovascular Interventions.
